Announcements Trials

Browse Landscape Eligibility

Clinical Trials

1 trials

Recent Start date Enrollment

Phase 3 × Enrolling by invitation × Afatinib × Clear all

Phase

Status

Completed 12 Terminated 1 Recruiting 1 Enrolling by invitation 1

Sponsor Class

Study Type

Interventional 1

Sponsor

Cancer Type

Conditions

Carcinoma, Non-Small-Cell Lung 1

Interventions

zilucoplan 1 zanidatamab 1 tislelizumab 1 sitravatinib 1 rozanolixizumab 1 pamiparib 1 lenvatinib 1 fludarabine phosphate 1 fludarabine 1 exemestane 1 epigallocatechin gallate 1 durvalumab 1 aumolertinib 1 atropine sulfate-diphenoxylate hydrochloride drug combination 1 Vincristine 1 Temozolomide 1 Tamoxifen 1 Sodium Chloride 1 R-CHOP protocol 1 Prednisone 1 Pemetrexed 1 Omeprazole 1 Melphalan 1 Loperamide 1 Letrozole 1 High-Energy Shock Waves 1 HMPL-013 1 Gastroscopy 1 Etoposide 1 Doxorubicin 1

Date Range

30 days 90 days 1 year All

Options

Has results Has announcements

NCT06759857 2025-01-06

FHND9041

Jiangsu Chia Tai Fenghai Pharmaceutical Co., Ltd.

Phase 3 Enrolling by invitation

Carcinoma, Non-Small-Cell Lung

Data powered by HemOnc (CC BY 4.0) Colophon ⚡